IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9757424 B1

PDFFull Text
Date of Patent:
Sep. 12, 2017

Filed:

Sep. 25, 2012

Compositions and methods of treating gliomas

Applicant:

Biomed Valley Discoveries, Inc., Kansas City, MO (US);

Inventors:

Reza Halse, Kansas City, MO (US);

Saurabh Saha, Leawood, KS (US);

Jeffrey James Roix, Boston, MA (US);

Assignee:

Biomed Valley Discoveries, Inc., Kansas City, MO (US);

Attorney:

Bryan Cave LLP

Primary Examiner:

Jeffrey S Lundgren

Assistant Examiner:

Meghan Finn

Int. Cl.
CPC ...
A61K 31/4184 (2006.01); A61K 38/08 (2006.01); A61K 45/06 (2006.01); A61K 31/41 (2006.01); A61K 31/4188 (2006.01); A61K 38/13 (2006.01); A61K 31/137 (2006.01); A61K 31/155 (2006.01); A61K 31/165 (2006.01); A61K 31/166 (2006.01); A61K 31/167 (2006.01); A61K 31/197 (2006.01); A61K 31/235 (2006.01); A61K 31/401 (2006.01); A61K 31/403 (2006.01); A61K 31/404 (2006.01); A61K 31/4045 (2006.01); A61K 31/4168 (2006.01); A61K 31/4178 (2006.01); A61K 31/42 (2006.01); A61K 31/433 (2006.01); A61K 31/4422 (2006.01); A61K 31/472 (2006.01); A61K 31/517 (2006.01); A61K 31/5415 (2006.01); A61K 31/55 (2006.01); A61K 31/554 (2006.01); A61K 31/675 (2006.01); A61K 38/12 (2006.01);
U.S. Cl.
CPC ...
A61K 38/08 (2013.01); A61K 31/137 (2013.01); A61K 31/155 (2013.01); A61K 31/165 (2013.01); A61K 31/166 (2013.01); A61K 31/167 (2013.01); A61K 31/197 (2013.01); A61K 31/235 (2013.01); A61K 31/401 (2013.01); A61K 31/403 (2013.01); A61K 31/404 (2013.01); A61K 31/4045 (2013.01); A61K 31/41 (2013.01); A61K 31/4168 (2013.01); A61K 31/4178 (2013.01); A61K 31/4184 (2013.01); A61K 31/4188 (2013.01); A61K 31/42 (2013.01); A61K 31/433 (2013.01); A61K 31/4422 (2013.01); A61K 31/472 (2013.01); A61K 31/517 (2013.01); A61K 31/5415 (2013.01); A61K 31/55 (2013.01); A61K 31/554 (2013.01); A61K 31/675 (2013.01); A61K 38/12 (2013.01); A61K 38/13 (2013.01); A61K 45/06 (2013.01);
Abstract

The present invention provides, inter alia, methods for treating or ameliorating the effects of a glioma. Methods of this invention include administering to a subject in need thereof an effective amount of a first active agent, such as e.g., an angiotensin receptor blocker, an antifungal agent, a bisphosphonate, an oxytocin inhibitor, an interleukin-1 (IL-1) inhibitor, a cyclooxygenase inhibitor, an α2δ voltage-dependent calcium channel (VDCC) inhibitor, a dihydroorotate dehydrogenase inhibitor, a calcium channel blocker, a renal sodium-chloride symporter inhibitor, an a2 adrenergic agonist, a phenothiazine antipsychotic, a calcineurin inhibitor, a 5-HT agonist, an angiotensin-converting enzyme (ACE) inhibitor, a direct rennin inhibitor, or combinations thereof, and a second active agent, which is a chemotherapeutic agent. Compositions for treating or ameliorating the effects of a glioma are also provided.

Find Patent Forward Citations

Loading…